Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride
liposome work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving lapatinib together with doxorubicin
hydrochloride liposome may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of doxorubicin
hydrochloride liposome when given together with lapatinib in treating patients with
metastatic breast cancer.